Skip to main content
Erschienen in: Pituitary 3/2013

01.09.2013

12-Month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency

verfasst von: Beverly M. K. Biller, Hyi-Jeong Ji, Hyunji Ahn, Conrad Savoy, E. Christine Siepl, Vera Popovic, Mihail Coculescu, Josefine Roemmler, Catalin Gavrila, David M. Cook, Christian J. Strasburger

Erschienen in: Pituitary | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The weekly sustained-release recombinant human GH formulation LB03002, showed beneficial effects in GH-deficient (GHD) adults in a previous 26-week double-blind study. Prior studies of long-acting GH preparations in adults have only been conducted for 6 or 8 months, so the effects of longer-term use are unknown; this is important to address, as replacement is given for many years in GHD adults. This open-label, 26-week study extension evaluated longer-term safety and efficacy of LB03002 over 52 weeks in adults with GHD who had previously been randomized to GH, and provides additional safety and efficacy data over 26 weeks in the cohort who had previously been randomized to placebo. Of 147 adults with GHD who completed a preceding study, 136 patients continued in this open-label study to receive LB03002 over an additional 26 weeks. This represented a continuation of long-acting GH for 26 weeks in the cohort who took this medication in the prior study (LB03002 Throughout group), and describes the first use of long-acting GH in the cohort that was randomized to placebo in the prior study (Switched to LB03002 group). The LB03002 dose was adjusted according to serum insulin-like growth factor-I (IGF-I) levels. LB03002 treatment demonstrated mean significant decreases from baseline in fat mass (FM) for both 26 (Switched group, P = 0.001) and 52 weeks (Throughout group, P = 0.002) of 1.11 (1.95) kg and 1.06 (3.16) kg, respectively. Prolonged GH treatment was effective in sustaining the increase in lean body mass (LBM), serum IGF-I and IGFBP-3 levels achieved during the first 26 weeks. Long-term treatment with the sustained-release weekly GH preparation over both 26 and 52 weeks in adults with GHD demonstrated a sustained reduction of FM with a favorable safety profile. This study extends prior knowledge about long-acting GH because it reports the most prolonged treatment of adults with any long-acting GH preparation, thereby confirming the value and safety of such agents for long-term GH replacement.
Literatur
1.
Zurück zum Zitat Rosenfeld RG, Bakker B (2008) Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 14:143–154PubMedCrossRef Rosenfeld RG, Bakker B (2008) Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 14:143–154PubMedCrossRef
2.
Zurück zum Zitat Reiter EO, Attie KM, Moshang T Jr, Silverman BL, Kemp SE, Neuwirth RB, Ford KM, Saenger P, Genentech Inc.-Alkermes Inc. Collaborative Study Group (2001) A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J Clin Endocrinol Metab 86:4700–4706PubMedCrossRef Reiter EO, Attie KM, Moshang T Jr, Silverman BL, Kemp SE, Neuwirth RB, Ford KM, Saenger P, Genentech Inc.-Alkermes Inc. Collaborative Study Group (2001) A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J Clin Endocrinol Metab 86:4700–4706PubMedCrossRef
3.
Zurück zum Zitat Cook DM, Biller BM, Vance ML, Hoffman AR, Phillips LS, Ford KM, Benziger DP, Illeperuma A, Blethen SL, Attie KM, Dao LN, Reimann JD, Fielder PJ (2002) The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin depot) in GH deficient adults. J Clin Endocrinol Metab 87:4508–4514PubMedCrossRef Cook DM, Biller BM, Vance ML, Hoffman AR, Phillips LS, Ford KM, Benziger DP, Illeperuma A, Blethen SL, Attie KM, Dao LN, Reimann JD, Fielder PJ (2002) The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin depot) in GH deficient adults. J Clin Endocrinol Metab 87:4508–4514PubMedCrossRef
4.
Zurück zum Zitat Hoffman AR, Biller BMK, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T, Lippe B, Genentech Adult Growth Hormone Deficiency Study Group (2005) Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab 90:6431–6440PubMedCrossRef Hoffman AR, Biller BMK, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T, Lippe B, Genentech Adult Growth Hormone Deficiency Study Group (2005) Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab 90:6431–6440PubMedCrossRef
5.
Zurück zum Zitat Biller BMK, Ji H-J, Ahn H, Savoy C, Siepl EC, Popovic V, Coculescu M, Roemmler J, Gavrila C, Cook DM, Strasburger CJ (2011) Effects of once-weekly sustained-release growth hormone: double-blind, placebo-controlled study in adult growth hormone deficiency. J Clin Endocrinol Metab 96(6):1718–1726. doi:10.1210/jc.2010-2819 Biller BMK, Ji H-J, Ahn H, Savoy C, Siepl EC, Popovic V, Coculescu M, Roemmler J, Gavrila C, Cook DM, Strasburger CJ (2011) Effects of once-weekly sustained-release growth hormone: double-blind, placebo-controlled study in adult growth hormone deficiency. J Clin Endocrinol Metab 96(6):1718–1726. doi:10.​1210/​jc.​2010-2819
6.
Zurück zum Zitat American Diabetes Association (2010) Standards of medical care in diabetes-2010. Diabetes Care 33(Suppl 1):S11–S61CrossRef American Diabetes Association (2010) Standards of medical care in diabetes-2010. Diabetes Care 33(Suppl 1):S11–S61CrossRef
7.
Zurück zum Zitat Spielhagen C, Schwahn C, Moller K, Friedrich N, Kohlmann T, Moock J, Koltowska-Haggstrom M, Nauck M, Buchfelder M, Wallaschofski H (2011) The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Horm IGF Res 21:1–10PubMedCrossRef Spielhagen C, Schwahn C, Moller K, Friedrich N, Kohlmann T, Moock J, Koltowska-Haggstrom M, Nauck M, Buchfelder M, Wallaschofski H (2011) The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Horm IGF Res 21:1–10PubMedCrossRef
8.
Zurück zum Zitat Svensson J, Bengtsson BA (2009) Safety aspects of GH replacement. Eur J Endocrinol 161(Suppl 1):S65–S74PubMedCrossRef Svensson J, Bengtsson BA (2009) Safety aspects of GH replacement. Eur J Endocrinol 161(Suppl 1):S65–S74PubMedCrossRef
9.
Zurück zum Zitat Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML, T002 Study Group (2004) Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 89:3224–3233PubMedCrossRef Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML, T002 Study Group (2004) Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 89:3224–3233PubMedCrossRef
10.
Zurück zum Zitat Peterkova V, Arslanoglu I, Bolshova-Zukovskaya E, Romer T, Zdravkovic D, Kratzsch J, Ji HJ, Savoy C, Saenger P (2007) A randomized, double-blind study to assess the efficacy and safety of Valtropin, a biosimilar growth hormone, in children with growth hormone deficiency. Horm Res 68:288–293PubMedCrossRef Peterkova V, Arslanoglu I, Bolshova-Zukovskaya E, Romer T, Zdravkovic D, Kratzsch J, Ji HJ, Savoy C, Saenger P (2007) A randomized, double-blind study to assess the efficacy and safety of Valtropin, a biosimilar growth hormone, in children with growth hormone deficiency. Horm Res 68:288–293PubMedCrossRef
11.
Zurück zum Zitat Pirazolli P, Cacciari E, Mandini M, Cicognani A, Zucchini S, Sganga T, Capelli M (1995) Follow-up of antibodies to growth hormone in 210 growth hormone-deficient children treated with different commercial preparations. Acta Pediatr 84:1233–1236CrossRef Pirazolli P, Cacciari E, Mandini M, Cicognani A, Zucchini S, Sganga T, Capelli M (1995) Follow-up of antibodies to growth hormone in 210 growth hormone-deficient children treated with different commercial preparations. Acta Pediatr 84:1233–1236CrossRef
12.
Zurück zum Zitat Riente L, Chimenti D, Pratesi F, Sedie AD, Tommasi S, Tommasi C, Bombardieri S, Migliorini P (2004) Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol 31:920–924PubMed Riente L, Chimenti D, Pratesi F, Sedie AD, Tommasi S, Tommasi C, Bombardieri S, Migliorini P (2004) Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol 31:920–924PubMed
13.
Zurück zum Zitat Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J (2004) Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 135:490–496PubMedCrossRef Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J (2004) Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 135:490–496PubMedCrossRef
Metadaten
Titel
12-Month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency
verfasst von
Beverly M. K. Biller
Hyi-Jeong Ji
Hyunji Ahn
Conrad Savoy
E. Christine Siepl
Vera Popovic
Mihail Coculescu
Josefine Roemmler
Catalin Gavrila
David M. Cook
Christian J. Strasburger
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 3/2013
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-012-0422-8

Weitere Artikel der Ausgabe 3/2013

Pituitary 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.